Invitation to earnings call for interim report January-September 2021

Report this content

On November 10, 08.00 (CET), the interim report January-September 2021 will be published and in connection with this, an earnings call will be arranged at 14:00 (CET) the same day. The earnings call will be available afterwards on the company’s website.

Presentation material will be available at and the presentation will be held in English.

Date: Wednesday, November 10, 2021. 14:00 (CET)
For audio: +46 8 502 439 36 Conference-ID: 733 136 669#
For video: Video link to the presentation
Speakers: Erik Gatenholm, CEO, Gusten Danielsson, CFO and Jonas Schöndube, Business Area Director Biosciences

Please note for the Q&A session you have two options: a) if you participate via audio, you can ask your questions directly to the speakers b) if you participate via video, you can only ask questions via the chat function.

For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890

This information was submitted for publication, through the agency of the contact persons set out above, on November 5, 2021, at 08:00 (CET).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO.